This study demonstrated that the 99mTc-IL2 scan might provide a tool for the in vivo assessment of tumor-infiltrating IL-2R-positive cells, which could be extremely beneficial for patient selection with unlabeled IL2 immunotherapy. The gene discussed is IL2; the disease is neoplasm.